Clinical Trials
16
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors
- Conditions
- Solid Tumor
- Interventions
- Combination Product: Pembrolizumab
- First Posted Date
- 2025-04-17
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Byondis B.V.
- Target Recruit Count
- 85
- Registration Number
- NCT06932952
Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.
- Conditions
- Relapsed / Refractory MDSRelapsed / Refractory AML
- Interventions
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Byondis B.V.
- Target Recruit Count
- 100
- Registration Number
- NCT06359002
- Locations
- 🇧🇪
Het Ziekenhuisnetwerk Antwerpen, Antwerpen, Belgium
🇧🇪UZ Leuven, Leuven, Belgium
🇳🇱Universitair Medisch Centrum Groningen, Groningen, Netherlands
First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228
- Conditions
- Lymphoma
- Interventions
- Drug: BYON4228 + Rituximab
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Byondis B.V.
- Target Recruit Count
- 100
- Registration Number
- NCT05737628
- Locations
- 🇮🇹
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS IRST, Ravenna, Italy
🇮🇹ASST Spedali Civili di Brescia, Brescia, Italy
🇮🇹Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia - IRCCS, Candiolo, Italy
A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Byondis B.V.
- Target Recruit Count
- 31
- Registration Number
- NCT05323045
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇮🇹Istituto Europeo di Oncologia, Milan, Italy
🇳🇱Radboud, Nijmegen, Netherlands
Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985
- Conditions
- Metastatic Breast Cancer
- Interventions
- Drug: BYON5667 & SYD985Drug: Placebo & SYD985
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Byondis B.V.
- Target Recruit Count
- 48
- Registration Number
- NCT04983238
- Locations
- 🇧🇪
University Hospital Antwerp, Antwerp, Belgium
🇧🇪UZ Leuven, Leuven, Belgium
🇫🇷Institut Bergonié, Bordeaux, France
- Prev
- 1
- 2
- Next
News
Novel HER2-Targeted Therapies Show Promise in Advanced Breast Cancer
Trastuzumab duocarmazine significantly improves progression-free survival compared to physician's choice in pretreated HER2-positive metastatic breast cancer patients.